BUD Down 5.5% In A Day. History Shows It Can Get Worse.
How did Anheuser-Busch InBev SA/NV (BUD) do vs the market during past crises?
Turns out, the stock has fared much worse than the S&P 500 index during various economic downturns.
2022 Inflation Shock
- BUD stock fell 43.4% from a high of $79.35 on 15 June 2021 to $44.90 on 11 October 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
- The stock is yet to recover to its pre-Crisis high
- The highest the stock has reached since then is $71.70 on 12 June 2025 , and currently trades at $66.35
| BUD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -43.4% | -25.4% |
| # of Days for Full Recovery | Not Fully Recovered | 464 |
2020 Covid Pandemic
- BUD Stock: Is $60 The Right Price?
- DEO Stock vs. BUD Stock
- Why Did BUD Stock Fall 8%?
- Why Is Anheuser-Busch InBev Stock Down 10%?
- Will Anheuser-Busch InBev (BUD) Stock Recover To Its 2021 Highs of $80?
- What’s Next For Anheuser-Busch InBev (BUD) Stock After A 7% Fall This Year Despite Q4 Earnings Beat?
- BUD stock fell 57.8% from a high of $83.45 on 2 January 2020 to $35.18 on 18 March 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
- The stock is yet to recover to its pre-Crisis high
| BUD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -57.8% | -33.9% |
| # of Days for Full Recovery | Not Fully Recovered | 148 |
2018 Correction
- BUD stock fell 48.1% from a high of $126.02 on 17 October 2017 to $65.43 on 24 December 2018 vs. a peak-to-trough decline of 19.8% for the S&P 500.
- The stock is yet to recover to its pre-Crisis high
| BUD | S&P 500 | |
|---|---|---|
| % Change from Pre-Recession Peak | -48.1% | -19.8% |
| # of Days for Full Recovery | Not Fully Recovered | 120 |
Worried that BUD could fall much more? You could take a look at the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.